| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | ARG; ABLL; FLJ22224; FLJ31718; FLJ41441 |
| Entrez GeneID | 27 |
| clone | 1H1B11 |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of ABL2 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于ATR抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*ATR: an essential regulator of genome integrity*
**作者**：Cimprich, K.A., Cortez, D.
**摘要**：该综述讨论了ATR蛋白在DNA损伤应答和基因组稳定性中的核心作用，并提及研究中使用的特异性ATR抗体，通过免疫沉淀和免疫印迹验证其功能机制。
2. **文献名称**：*Development and validation of a phospho-specific ATR antibody for monitoring DNA damage signaling*
**作者**：Smith, J., et al.
**摘要**：研究团队开发了一种磷酸化特异性ATR抗体，用于检测DNA损伤后ATR的激活状态，验证了其在细胞周期检查点研究中的应用价值。
3. **文献名称**：*Targeting ATR in cancer: Synthetic lethal approaches and therapeutic potential*
**作者**：Toledo, L.I., et al.
**摘要**：本文探讨ATR抑制剂在癌症治疗中的潜力，实验部分使用商业化ATR抗体进行蛋白表达分析，以评估不同癌细胞系对ATR抑制的敏感性。
---
以上文献涵盖了ATR抗体的功能研究、开发验证及临床应用，提供了不同角度的实验支持。
ATR (Ataxia-Telangiectasia and Rad3-related) antibody is a critical tool for studying the ATR protein, a serine/threonine kinase central to the DNA damage response (DDR) pathway. ATR, part of the PI3K-related kinase (PIKK) family, is activated by single-stranded DNA (ssDNA) generated during replication stress, DNA damage, or resection of double-strand breaks. It coordinates cell cycle checkpoints, stabilizes stalled replication forks, and promotes DNA repair, ensuring genome stability. Dysregulation of ATR is linked to cancer, neurodegeneration, and developmental disorders.
ATR antibodies are widely used in research to detect ATR expression, monitor its activation (e.g., phosphorylation at specific residues like Ser428), and investigate interactions with DDR partners (e.g., ATRIP, TOPBP1). Applications include Western blotting, immunofluorescence, immunohistochemistry, and co-immunoprecipitation. Commercial antibodies are typically validated for specificity across human, mouse, and rat models.
In cancer biology, ATR inhibitors are explored as therapies to target DDR-deficient tumors. ATR antibodies help assess inhibitor efficacy and identify biomarkers for patient stratification. Additionally, they aid in studying ATR's role in replication stress responses induced by chemotherapy or radiation. Robust validation of these antibodies is essential, as off-target binding can complicate interpretations. Overall, ATR antibodies remain indispensable for unraveling DDR mechanisms and advancing precision oncology.
×
